help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elks, M. L.
Right arrow Articles by Manganiello, V. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elks, M. L.
Right arrow Articles by Manganiello, V. C.

Endocrinology, Vol 115, 1262-1268, Copyright © 1984 by Endocrine Society


ARTICLES

Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes

ML Elks and VC Manganiello

3T3-L1 adipocytes contain both soluble and particulate cAMP phosphodiesterases which can be distinguished by several criteria. Particulate phosphodiesterase activity of 3T3-L1 adipocytes, but not undifferentiated fibroblasts, was selectively increased by incubation of cells with insulin or lipolytic hormones. Particulate cAMP phosphodiesterase activity from 3T3-L1 adipocytes was very sensitive to inhibition by cilostamide in an apparently competitive fashion. Particulate activity from undifferentiated 3T3-L1 fibroblasts or supernatant activity from either type of cell was much less sensitive to cilostamide. On the other hand, supernatant cAMP phosphodiesterase activity from both undifferentiated fibroblasts and 3T3-L1 adipocytes was very sensitive to inhibition by Ro-20-1724 in an apparently competitive fashion. Ro-20-1724 was not an effective inhibitor of particulate activity from either type of cell. In fractions from 3T3-L1 adipocytes, isobutylmethylxanthine (IBMX) effectively inhibited both supernatant and particulate cAMP phosphodiesterase activities. In addition, however, IBMX was relatively more specific in inhibiting supernatant calmodulin-activated cGMP phosphodiesterase activity than supernatant calmodulin-independent or particulate cGMP phosphodiesterase activities. In intact 3T3-L1 adipocytes, cilostamide enhanced lipolysis in the absence or presence of isoproterenol and had no effect on cAMP content in the presence of low concentrations of isoproterenol. Ro-20-1724 increased lipolysis to a lesser extent than cilostamide and did not enhance isoproterenol-stimulated lipolysis, but did increase isoproterenol-stimulated accumulation of cAMP to a greater extent than cilostamide. Like cilostamide, Ro-20-1724 did not enhance accumulation of cAMP in the absence of isoproterenol. IBMX enhanced lipolysis and cAMP accumulation with or without isoproterenol. Taken together, these results support the idea that although particulate and soluble low Km phosphodiesterases influence cAMP content, the particulate enzyme may be more important in the metabolism of cAMP involved in the regulation of lipolysis. Since combinations of Ro-20- 1724 and cilostamide were not as effective as IBMX in increasing cAMP content, perhaps the calmodulin-dependent phosphodiesterase, which is selectively inhibited by IBMX, is also involved in the regulation of total cell cAMP content.


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
H. Wang and N. K. Edens
mRNA expression and antilipolytic role of phosphodiesterase 4 in rat adipocytes in vitro
J. Lipid Res., May 1, 2007; 48(5): 1099 - 1107.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
J. Cheng and J. P. Grande
Cyclic Nucleotide Phosphodiesterase (PDE) Inhibitors: Novel Therapeutic Agents for Progressive Renal Disease
Experimental Biology and Medicine, January 1, 2007; 232(1): 38 - 51.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
P. B. Snyder, J. M. Esselstyn, K. Loughney, S. L. Wolda, and V. A. Florio
The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis
J. Lipid Res., March 1, 2005; 46(3): 494 - 503.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
J. Cheng, M. A. Thompson, H. J. Walker, C. E. Gray, M. M. Diaz Encarnacion, G. M. Warner, and J. P. Grande
Differential regulation of mesangial cell mitogenesis by cAMP phosphodiesterase isozymes 3 and 4
Am J Physiol Renal Physiol, November 1, 2004; 287(5): F940 - F953.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
E. L. Arrese, M. T. Flowers, J. L. Gazard, and M. A. Wells
Calcium and cAMP are second messengers in the adipokinetic hormone-induced lipolysis of triacylglycerols in Manduca sexta fat body
J. Lipid Res., March 1, 1999; 40(3): 556 - 564.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
C. C.S. Chini, J. P. Grande, E. N. Chini, and T. P. Dousa
Compartmentalization of cAMP Signaling in Mesangial Cells by Phosphodiesterase Isozymes PDE3 and PDE4. REGULATION OF SUPEROXIDATION AND MITOGENESIS
J. Biol. Chem., April 11, 1997; 272(15): 9854 - 9859.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society